Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

When Sherry Mansour, MD, assistant professor of medicine (nephrology), first began her training at Yale, she was struck by ...

A scientific statement has been published by the AHA and ACC regarding using risk assessment for BP management for prevention of CVD.

Rochester, Minn.-based Mayo Clinic has developed a framework that uses computer modeling and electronic health records to simulate “virtual clinical trials” for heart failure treatments. Researchers ...

The first artificial intelligence (AI) stethoscope has gone beyond listening to a heartbeat. Researchers at Imperial College London and Imperial College Healthcare NHS Trust discovered that an AI ...

New research reveals a strong link between a common liver disease affecting nearly 90 million Americans and heart failure, with nearly half of patients showing early signs of heart damage. Researchers ...

New research highlights a significant link between metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, and an increased risk of heart failure, even independent of ...

Wearable technology has seamlessly integrated into our everyday lives, offering convenience and critical health insights.

Disparities in education and access to insurance mean that heart failure hits Black American adults nearly 14 years earlier than it does White Americans, new research shows. Among Black patients, ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...

Boise, Idaho-based St. Luke’s Regional Medical Center had the lowest 30-day readmission rate for heart failure patients between July 1, 2021, and June 30, 2024, according to CMS data published Aug. 6.

This news might break your heart — literally. A shocking new study found that the go-to treatment doctors have been using to manage heart attacks for the last 40 years may offer no real benefit for ...